Literature DB >> 16141201

Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor.

Liang-Nian Song1, Edward P Gelmann.   

Abstract

The multifunctional oncoprotein beta-catenin interacts with the activation function-2 domain of androgen receptor (AR) to stimulate androgen receptor transcriptional activity, increase sensitivity, and broaden specificity of ligand interactions. beta-Catenin interacts with androgen receptor in close proximity to the binding groove for P160 coactivators such as transcriptional intermediary factor-2 (TIF2)/glucocorticoid receptor interacting protein-1 (GRIP1). beta-Catenin can also bind directly to TIF2/GRIP1. Both N- and C-terminal regions of beta-catenin are needed for optimal interaction with TIF2/GRIP1. We show that distinct residues of beta-catenin are responsible for both binding and functional interactions with androgen receptor and with TCF4, thus allowing the introduction of missense mutations that selectively affect these interactions. beta-Catenin and TIF2/GRIP1 are each able to mediate binding between the other and androgen receptor in functional interactions that enhance ligand-dependent transcription. The data strongly imply that AR, beta-catenin, and TIF2/GRIP1 bind in a three-way interaction that mediates transcription. Lastly, we observed that a beta-catenin C-terminal peptide containing 229 amino acids can bind TIF2/GRIP1 and AR but has a profound dominant inhibitory effect on ligand-dependent transcription. We propose that beta-catenin may play an integral role in formation of the androgen-receptor transcriptional complex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141201     DOI: 10.1074/jbc.M503850200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  FOXA1: master of steroid receptor function in cancer.

Authors:  Michael A Augello; Theresa E Hickey; Karen E Knudsen
Journal:  EMBO J       Date:  2011-09-20       Impact factor: 11.598

2.  Biochemical and structural characterization of β-catenin interactions with nonphosphorylated and CK2-phosphorylated Lef-1.

Authors:  Jinglucy Sun; William I Weis
Journal:  J Mol Biol       Date:  2010-11-12       Impact factor: 5.469

3.  Role of the N-terminal activation domain of the coiled-coil coactivator in mediating transcriptional activation by beta-catenin.

Authors:  Catherine K Yang; Jeong Hoon Kim; Michael R Stallcup
Journal:  Mol Endocrinol       Date:  2006-08-24

4.  Epithelial-Mesenchymal Transition Markers β-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study.

Authors:  Tumay Ipekci; Ferhat Ozden; Betul Unal; Caner Saygin; Didem Uzunaslan; Erhan Ates
Journal:  Pathol Oncol Res       Date:  2015-06-04       Impact factor: 3.201

Review 5.  Revisiting the role of Wnt/β-catenin signaling in prostate cancer.

Authors:  Jeffrey A Schneider; Susan K Logan
Journal:  Mol Cell Endocrinol       Date:  2017-02-09       Impact factor: 4.102

Review 6.  Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.

Authors:  Teodora Ribarska; Klaus-Marius Bastian; Annemarie Koch; Wolfgang A Schulz
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

7.  Inhibition of androgen receptor and β-catenin activity in prostate cancer.

Authors:  Eugine Lee; Aviv Madar; Gregory David; Michael J Garabedian; Ramanuj Dasgupta; Susan K Logan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-09       Impact factor: 11.205

8.  Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.

Authors:  Murali M Yallapu; Sheema Khan; Diane M Maher; Mara C Ebeling; Vasudha Sundram; Neeraj Chauhan; Aditya Ganju; Swathi Balakrishna; Brij K Gupta; Nadeem Zafar; Meena Jaggi; Subhash C Chauhan
Journal:  Biomaterials       Date:  2014-07-12       Impact factor: 12.479

9.  Wnt signaling in castration-resistant prostate cancer: implications for therapy.

Authors:  Noriko N Yokoyama; Shujuan Shao; Bang H Hoang; Dan Mercola; Xiaolin Zi
Journal:  Am J Clin Exp Urol       Date:  2014-04-15

Review 10.  Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family.

Authors:  Jianming Xu; Ray-Chang Wu; Bert W O'Malley
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.